Pine Labs has raised $75-$100 million led by US-based billionaire Stephen Mandel's hedge fund Lone Pine Capital, valuing the Noida-based merchant-commerce startup at more than...
Keep Reading →
December 21 - Hedge Funds, Insider Trading - Comments
A whopping number of 13F filings filed with U.S.
Keep Reading →
December 12 - Hedge Funds, News - Comments
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Keep Reading →
July 4 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Keep Reading →
December 19 - Hedge Funds, News - Comments
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Keep Reading →
October 30 - Hedge Funds, News - Comments
Is Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Keep Reading →
June 26 - Hedge Funds, News - Comments
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources...
Keep Reading →
May 5 - Hedge Funds, News - Comments
Billionaire hedge fund manager William Ackman, whose investment assets have shrunk by more than half in the last three years, has made a second round of staff cuts and laid off...
Keep Reading →
June 27 - Hedge Funds, Insider Trading - Comments
The 50-year-old definition of capitalism in the U.S.
Keep Reading →
June 12 - Hedge Funds, Insider Trading - Comments
Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts.
Keep Reading →
March 1 - News, Stock Analysis - Comments
Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector.
Keep Reading →
December 6 - Market Movers, News, Stock Analysis - Comments
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset...
Keep Reading →
December 2 - Hedge Funds, News - Comments
When things go well in biotech, it can be a great ride.
Keep Reading →
September 16 - News, Stock Analysis - Comments
Lexicon Pharmaceuticals, Inc.
Keep Reading →
September 13 - News, Stock Analysis - Comments
It is already common knowledge that individual investors do not usually have the necessary resources and ability to properly research an investment opportunity.
Keep Reading →
November 23 - Hedge Funds, News - Comments
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic and anti-inflammatory ...
Keep Reading →
September 23 - Hedge Funds, News - Comments
Shares of Lexicon Pharmaceuticals, Inc.
Keep Reading →
August 3 - Hedge Funds, News - Comments
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Keep Reading →
September 17 - News - Comments
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
Keep Reading →
September 11 - News - Comments
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Keep Reading →
September 3 - News - Comments
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Keep Reading →
August 30 - News - Comments
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Keep Reading →
August 30 - News - Comments
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
Keep Reading →
August 22 - News - Comments
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at $500 million or more written...
Keep Reading →
July 24 - News - Comments
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
Keep Reading →
June 21 - News - Comments
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Keep Reading →
June 12 - News - Comments
It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors.
Keep Reading →
June 3 - News - Comments
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
Keep Reading →
June 3 - News - Comments
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Keep Reading →
June 3 - News - Comments
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
Keep Reading →
April 12 - News - Comments
The global economy is still going through the initial stages of recovery and waiting on positive news from European markets.
Keep Reading →
March 19 - Insider Trading - Comments
